In the final days of the Biden administration, the U.S. Department of Health and Human Services’ Centers for Medicare and ...

Boston Scientific Corp. reported positive data for two key atrial fibrillation therapies at AF Symposium 2025 on January 17.

Having 35 copies of the CAG triplet in the gene that causes Huntington’s disease is not a problem. Inheriting 40 could be a ...

Medtronic plc’s next-generation pill-sized camera saw its first use in a recent appointment, during which it captured thousands of high-definition images of the small bowel mucosa. The company hopes ...

China is deepening its regulatory reforms of drugs and devices to foster a globally competitive innovation ecosystem to ...

Atara Biotherapeutics Inc. received a complete response letter from the U.S. FDA for its lead product Ebvallo (tabelecleucel), a breakthrough therapy for Epstein-Barr virus positive post-transplant ...

Bristol Myers Squibb Co. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety coupled to a DNA-binding protein Ikaros (IKZF1 ...

Axcynsis Therapeutics Pte Ltd. has gained IND clearance from the FDA for AT03-65 for the treatment of patients with CLDN6-positive solid tumors. Axcynsis is planning to initiate a phase I trial in the ...

According to the World Health Organization (WHO), multidrug-resistant pathogens caused over 1.27 million deaths worldwide in ...

In a deal potentially worth $810 million for Regenxbio Inc., Nippon Shinyaku Co. Ltd. is partnering on the U.S. and Asian development and commercialization of iduronate-2-sulfatase enzyme RGX-121 for ...

TC Biopharm (Holdings) plc intends to begin proof-of-concept preclinical studies for its lead therapeutic TCB-008, to treat H5N1, or bird flu. TCB-008 is an allogeneic, unmodified cell therapy ...

The EMA recommended the highest number of approvals in the last 15 years in 2024, giving the nod to 114 drugs. That is amongst the highest number in the 30 years of the agency’s existence, said ...